Aptose Biosciences Inc. (APTO) Expected to Post Earnings of -$0.17 Per Share

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to report earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aptose Biosciences’ earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.15). Aptose Biosciences posted earnings of ($0.23) per share in the same quarter last year, which indicates a positive year over year growth rate of 26.1%. The firm is scheduled to announce its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.69). For the next year, analysts expect that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($0.94) to ($0.72). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01).

Several research analysts have commented on the company. Zacks Investment Research downgraded Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, March 26th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a report on Friday, March 22nd. Roth Capital reiterated a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, December 12th. Citigroup began coverage on Aptose Biosciences in a report on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target on the stock. Finally, Royal Bank of Canada initiated coverage on Aptose Biosciences in a report on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Aptose Biosciences currently has an average rating of “Buy” and an average target price of $5.75.

APTO opened at $1.98 on Thursday. The firm has a market cap of $77.66 million, a price-to-earnings ratio of -2.30 and a beta of 1.61. Aptose Biosciences has a 52 week low of $1.57 and a 52 week high of $4.55.

In related news, CFO Gregory K. Chow acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was acquired at an average price of $1.75 per share, with a total value of $26,250.00. Following the acquisition, the chief financial officer now directly owns 122,014 shares in the company, valued at approximately $213,524.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here.

Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC purchased a new position in shares of Aptose Biosciences in the 4th quarter valued at $33,000. Noven Financial Group Inc. acquired a new stake in shares of Aptose Biosciences in the 4th quarter worth $27,000. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Aptose Biosciences by 11.4% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 5,890 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Aptose Biosciences by 1,130.9% in the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 168,501 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Aptose Biosciences in the 3rd quarter worth $125,000. 7.88% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Story: Special Dividends

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.